Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Raises $6.3M

NEW YORK (GenomeWeb) – Courtagen Life Sciences has raised about $6.3 million, the genetic testing firm disclosed in a document filed with the US Securities and Exchange Commission this week.

Courtagen did not disclose the identity of the investors or say how proceeds will be used. It did not respond to requests seeking clarification.

The Woburn, Mass.-based company develops tests for mitochondrial disorders, epilepsy and seizure disorders, Autism Spectrum Disorder, and other conditions based on next-generation sequencing technology. This week, it announced a deal with Seizure Tracker aimed at epilepsy.

In May it and Sciencewerke reached an agreement for the distribution of Courtagen's clinical NGS tests, and the month before that Courtagen and Connecticut Children's Medical Center said they would collaborate to identify alterations in genes associated with ASD.